Article
Value of Superselective Ophthalmic Artery Chemotherapy with Melphahlan for Retinoblastoma
Search Medline for
Authors
Published: | September 21, 2010 |
---|
Outline
Text
Background: Retinoblastoma requires multiple therapeutical approaches concerning Stage and Laterality. The Superselective Ophthalmic Artery Chemotherapy via the Femoral Artery is a recent development with a controversial discussion.
Methods: We report about our experiences of 7 interventions of 6 patients. We overview the possible indications according to the stage of disease.
Results: 4 of 7 planned interventions with 3 mg Melphalan succeeded. 3 patients have been treated one time, one patient two times. Because of anatomical reasons the intervention failed in three cases. The tumours showed a good response. Transient side effects are limited to neutropenia, lid edema, supraorbital hyperemia and loss of lashes.
Conclusions: Superselective Ophthalmic Artery Chemotherapy with Melphalan depicts a promising approach. Longtime benefit and complications couldn’t be valued right now. In a well circumscribed manner, this procedure delivers an important option: 1. Bilateral retinoblastoma with relapse after established globe preserving therapies to prevent the enucleation. 2. Unilateral retinoblastom with a lower or moderate stage of disease. This opportunity can be discussed as a possible more gentle alternative comparing to systemic chemoreduction following focal treatment.